Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Sees Large Drop in Short Interest

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the target of a large decrease in short interest in March. As of March 15th, there was short interest totalling 434,100 shares, a decrease of 19.6% from the February 28th total of 539,600 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 3.6% of the shares of the company are short sold.

Cyclo Therapeutics Stock Performance

NASDAQ:CYTH opened at $0.72 on Wednesday. The company has a market capitalization of $23.72 million, a P/E ratio of -0.80 and a beta of -0.57. Cyclo Therapeutics has a 12 month low of $0.55 and a 12 month high of $1.79. The firm has a fifty day simple moving average of $0.79 and a 200-day simple moving average of $0.73.

Institutional Trading of Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Two Sigma Securities LLC acquired a new position in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned about 0.15% of Cyclo Therapeutics as of its most recent SEC filing. 68.55% of the stock is owned by hedge funds and other institutional investors.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.